Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: A phase II study

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 7, 2000, Pages 791-798

  De Souza, C A ^a   Santini, G ^b   Marino, C ^b   Nati, S ^b   Congiu, A M ^b   Vigorito, A C ^a   Damasio, E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Amifostine; Cytoprotection; High dose cyclophosphamide; Non Hodgkin's lymphoma; Peripheral blood progenitor cell mobilization

Indexed keywords

ALKALINE PHOSPHATASE; AMIFOSTINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; HYPOTENSION; LIVER TOXICITY; LUNG TOXICITY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; STEM CELL;

EID: 0033860164     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000700009     Document Type: Article

References (22)

1. List AF, Heaton R, Glinsmann-Gibson B & Capizzi RL (1996). Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Seminars in Oncology, 23 (Suppl 8): 58-63.
2. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA & Ward JF (1988). Radio-protection of cells in culture by WR-2721 and derivates: Form of the drug responsible for protection. Cancer Research, 48: 3641-3647.
3. Calabro-Jones PM, Agulera JA, Ward JF, Smoluk GD & Fahey RC (1988). Uptake of WR-2721 derivates by cells in culture: Identification of the transported form of the drug. Cancer Research, 48: 3634-3640.
4. Capizzi RL (1996). The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethiol). European Journal of Cancer, 32 (Suppl 4): S5-S16.
5. Grdina DJ & Sigdestad CP (1989). Radiation protectors: The unexpected benefits. Drug, 20: 13-42.
6. Calabro-Jones PM, Fahey RC, Smoluk GD & Ward JF (1985). Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. International Journal of Radiation Biology, 47: 23-27.
7. Schuchter LM & Glick JH (1993). The current status of WR-2721 (amifostine): A chemotherapy and radiation therapy protector. Biology Therapy Cancer Updates, 3: 1-10.
8. Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SMJ & Culo F (1980). Treatment of tumors with the combination of WR-2721 and cisdichlorodiamine-platinum (II) or cyclophosphamide. British Journal of Cancer, 42: 574-585.
9. Yuhas JM (1980). A more general role for WR-2721 in cancer therapy. British Journal of Cancer, 41: 832-834.
10. Wasserman TH, Philips TL, Ross G & Kane LJ (1981). Differential protecton against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clinical Trials, 4: 3-6.
11. Bukowski RM (1996). Amifostine (Ethiol): Dosing, administration and patient management guidelines. European Journal of Cancer, 32A (Suppl 4): S46-S49.
12. Schuchter LM (1996). Guidelines for the administration of amifostine. Seminars in Oncology, 23 (Suppl 8): 40-43.
13. Glover DJ, Riley L & Carmichael K (1983). Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). New England Journal of Medicine, 309: 1137-1141.
14. U.S. Bioscience (1992). A phase I study to determine whether Ethiol (WR-2721) is a vasodilator when infused into the brachial artery of healthy volunteers. ETH CLPH 1.
15. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G, Stern A, Magni M & Caracciolo D (1997). High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine, 336: 1290-1297.
16. + cells in peripheral and cord blood by cytometry. Experimental Hematology, 22: 1003-1110.
17. Tarella C, Benedetti G, Caracciolo D, Castellino C, Cherasco C, Bondesan P, Omede P, Ruggieri D, Gianni M & Pileri A (1995). Both early and committed haematopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. British Journal of Haematology, 91: 535-543.
18. O'Reilly SE, Hoskins P, Klimo P & Connors JM (1991). MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ ABV in Hodgkin's disease. Annals of Oncology, 2 (Suppl 1): 17-23.
19. Schering-Plough International (1994). Ethiol (Amifostine) for the Prevention of Chemotherapy-Induced Toxicity [Product Monograph]. Schering-Plough International, Kenilworth, NJ, 37-44.
20. Glover DJ, Glick JH, Weiler C, Hurowitz S & Kligerman MM (1986). WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. Journal of Clinical Oncology, 4: 584-588.
21. Glover DJ, Fox KR, Weiler C, Kligerman MM, Turrisi A & Glick JH (1988). Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacology and Therapeutics, 39: 3-7.
22. Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL & Blaney SM (1995). A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Research, 55: 4069-4072.